Home
Gene Therapy
27 February - 28 February 2002
Gene Therapy
Gene therapy is a novel approach to treat, cure and ultimately prevent disease by changing the expression of a person’s gene. Gene therapy is still in the early experimental stages, due to the many factors that have prevented researchers from developing successful techniques. This conference aims to address these key factors as the potential for gene therapy continues to grow. As the first gene therapy products are expected to hit the market by 2003, this conference aims to cover the key issues and discuss them both in theoretical terms and through practical current case studies.

The topics covered at this Gene therapy conference will include practical issues such as delivery systems and diagnosing genetic defects. It will also cover in detail the application of gene therapy in the various therapeutic areas such as cancer, cardiovascular disease and HIV infection. Commercial issues, legal issues and ethical issues will also be discussed as well as the current market situation in order to keep all those involved in gene therapy up to date with the current issues and concepts.

Conference agenda

clock

8:30

Registration and Coffee

clock

9:00

Early marketing considerations

  • Market Research
  • Segmentation and Benchmarking
  • Pre-launch Marketing
  • clock

    9:00

    Genetic vaccination: an overview

  • Principles
  • Advantages over conventional vaccines
  • Questions to be solved
  • clock

    10:00

    Strategic marketing

  • Optimising opportunities
  • Identifying market strengths
  • Entering new markets
  • clock

    10:00

    Vectors for genetic vaccination

  • Viral vectors
  • Conventional plasmids
  • MIDGE vectors
  • clock

    11:00

    Morning Coffee

    clock

    11:15

    Communication Strategies

  • Which tools to use?
  • Power of the media
  • Making the most of your communication tools
  • clock

    11:15

    Production of DNA vectors

  • Expression cassettes
  • High throughput production
  • clock

    12:00

    Product positioning

  • Pricing considerations
  • Identifying niche marketing strategies
  • Competitor intelligence
  • clock

    12:00

    Quality control of nucleic acids produced under GMP

  • Quality control issues in GMP production
  • Lot release testing
  • Identity testing
  • Purity testing
  • Validation issues
  • clock

    12:45

    Lunch

    clock

    13:45

    Effective Branding

  • Building an image
  • Brand management
  • Brand positioning
  • clock

    13:45

    Efficacy of genetic vaccination

  • Adjuvant effects of DNA
  • CpG
  • clock

    14:45

    E-Marketing

  • The internet as a marketplace
  • Planning an effective online presence
  • Integrating the internet successfully into the marketing mix
  • clock

    14:45

    Applications

  • Infectious diseases
  • Cancer
  • Others
  • clock

    15:45

    Afternoon Tea

    clock

    16:00

    Future Trends & Challenges

  • Marketing to the individual
  • Future markets
  • Adapting business models to the changing marketplace
  • clock

    16:00

    Regulatory issues

    clock

    16:45

    Discussion

    clock

    17:00

    Close of Workshop

    clock

    8:30

    Registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Dominic Wells

    Dr Dominic Wells, Reader in Transgenic Biology, Imperial College of Science, Technology & Medicine

    clock

    9:10

    OVERVIEW

    Dr Andrew Mountain

    Dr Andrew Mountain, Research Director, Cobra Therapeutics

  • The importance of gene therapy
  • Exvivo and invivo approaches
  • Introduction to main vector types
  • Clinical history and status
  • Problems and progress in transgene expression
  • Issues for further development of gene therapy
  • clock

    9:40

    GENE THERAPY PRODUCTS

    Dr Douglas Jolly

    Dr Douglas Jolly, Chief Executive Officer, BioMedica

  • What is gene therapy good for?
  • Retro and lentiviral vectors - learn from the past, but its not the future
  • Neurological disease as a target
  • Putting lentivectors in the clinic
  • Why buy gene therapy now?
  • clock

    10:20

    LOCALIZED PRODUCTION OF THERAPEUTIC PROTEINS AT THE SITE OF DISEASE

    Dr Richter King

    Dr Richter King, Vice President, Research, GenVec

  • Advantages of using local delivery for the generation of gene therapy products
  • Adenovector technology for local gene delivery
  • Products for important medical needs based on local gene therapy
  • Targeted adenovectors to expand gene therapy product discovery
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    UNDERSTANDING THE VECTOR-GENE-DISEASE RELATIONSHIP

    Dr James McArthur

    Dr James McArthur, Principal Scientist, Senior Director, Preclinical Biology and Immunology, Cell Genesys

  • AAV immunity and the route of administration
  • Lentiviral vector immunity and the antigen presenting cell
  • Adenoviral vector pathology and the target issue
  • clock

    12:00

    HURDLES IN GENE THERAPY DELIVERY

    Dr Ronald Vogels

    Dr Ronald Vogels, Senior Scientist, Crucell

  • Hurdles for applications of adenovirus type-5 based vectors
  • Modifications to adenoviruses to avoid neutralising antibodies
  • Modifications to adenoviruses to improve tissue - specific gene delivery
  • Safe and cost-effective manufacturing of capsid - modified adenoviral vectors
  • clock

    12:40

    Networking Lunch

    clock

    14:00

    TRANZVECTOR - A NEXT GENERATION LENTIVIRAL VECTOR WITH ENHANCED SAFETY

    Dr Ram Ramabhadran

    Dr Ram Ramabhadran, Senior Vice President, Research & Development, Tranzyme

  • Design and advantages of TranzVector
  • Novel approaches to therapies for neuro-opthalmic diseases
  • Relevance of TranzVector in neuro-ophthalmic diseases
  • Identification of therapeutic genes and validation as targets
  • Development of cell and animal models
  • Therapeutic applications
  • clock

    14:40

    THE FUTURE OF PROTEIN DELIVERY

    Dr Albert Rauch

    Dr Albert Rauch, Managing Director, Ladenburg Thalmann

  • Underappreciated and misunderstood
  • Marching towards commercialisation
  • The right vector, for the right gene, for the right disease
  • Genomics, providing more proteins to deliver
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    ALTERNATIVE VECTORS FOR GENE THERAPY

    Dr Alain Rolland

    Dr Alain Rolland, Senior Vice President, Preclinical Research & Development, Valentis

  • From local applications to systemic gene delivery
  • Noncondensing polymers for delivery to solid tissues
  • Polymeric systems and electroporation for producing systemic proteins
  • Liposome-mediated gene transfer in oncology
  • Effectiveness of synthetic delivery systems in preclinical models
  • Safety and utility in gene therapy
  • clock

    16:20

    GENE DELIVERY AND VACCINES

    Dr Christian Hofmann

    Dr Christian Hofmann, Vice President, Vector Development, DeveloGen

  • Pre-existing immunity against human viral vectors
  • Non-human viral vectors for gene delivery
  • Efficiency and tropism in animal models
  • From potential to meaningful therapeutic applications
  • Prophylactic and therapeutic vaccines
  • Virus-based gene discovery engines
  • clock

    17:00

    Chairman's Closing Remarks and Close of Day One

    clock

    8:30

    Re-registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Hardev Pandha

    Dr Hardev Pandha, Senior Lecturer in Medical Oncology, St George’s Hospital Medical School

    clock

    9:10

    DISEASE TARGETED RESEARCH

    Dr Jack Reich

    Dr Jack Reich, Founder, Formerly Chairman & Chief Executive Officer, Collateral Therapeutics

  • Non-surgical cardiovascular angiogenesis
  • Invivo application
  • Dual recombinant angiogenic growth factor
  • Problems in treating cardiovascular diseases
  • Congestive heart failure
  • Possibilities for prevention
  • clock

    9:40

    PRE-CLINICAL AND CLINICAL STUDIES WITH ONYX-015: CURRENT PROGRESS AND FUTURE POTENTIAL

    Dr Scott Freeman

    Dr Scott Freeman, Vice President, Clinical Development, Onyx Pharmaceuticals

  • Replacement of tumour suppressor genes
  • Abnormalities in the P53 function
  • Exploiting genetic differences between normal and malignant cells
  • Targeting cancer cells
  • Multiple cancer fighting capabilities
  • Possibilities and restraints of ONYX-015
  • clock

    10:20

    DEVELOPING GENE MEDICINES

    Dr Alan Boyd

    Dr Alan Boyd, Director, Development, Ark Therapeutics

  • Moving from the research idea to the patient
  • Hitting the target site
  • Overcoming obstacles
  • Development of a cardiovascular gene medicine - TrinamTM
  • Development of a gene medicine for malignant Glioma - EG009
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    THERAPEUTIC ACTIVATION OF ENDOGENOUS GENES

    Dr John Girdlestone

    Dr John Girdlestone, Senior Scientist, Gendaq Ltd.

  • Engineered transcription factors
  • Gene repression
  • Gene activation
  • VEGF
  • Alternative splicing
  • Therapeutic angiogenesis
  • clock

    12:00

    TARGET VALIDATION

    Dr Julian Beesley

    Dr Julian Beesley, Director, Business Development, LifeSpan BioSciences

  • Gene selection
  • Molecular pathology
  • Target prioritization
  • Gene distribution
  • Potential toxicity
  • Evaluation in animal models

    Evaluation in human tissues

  • clock

    12:40

    Networking Lunch

    clock

    14:00

    FROM THE BENCH TO THE PHARMACY

    Dr Claas Junghans

    Dr Claas Junghans, General Manager, Mologen

  • The importance of choosing the right patient
  • The perfect target
  • Getting the technology together
  • Persuading the authorities
  • Getting there first
  • And then making money…
  • clock

    14:40

    FROM CONCEPT TO COMMERCIALISATION

    Dr Samuel Wadsworth

    Dr Samuel Wadsworth, Vice President, Gene Therapy Initiative, Genzyme

  • The commercial process
  • Effective financing
  • Building an infrastructure
  • Technological barriers
  • Importance of getting to the market first
  • Problems with commercialising gene therapies
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    REGULATIONS

    Dr Jayne Spink

    Dr Jayne Spink, Section Head, Genetic Science Policy, Gene Therapy Advisory Committee, Department of Health, UK

  • Clinical trials
  • Oversight of gene therapy
  • Ethical acceptability
  • Assessing the merits of gene therapy proposals
  • Obtaining regulatory approval
  • Current guidelines
  • clock

    16:20

    THE FUTURE OF GENE THERAPY

    Dr Barrie Carter

    Dr Barrie Carter, Executive Vice President & Chief Scientific Officer, Targeted Genetics

  • Potential for disease prevention
  • Erasing genetic diseases
  • Cost of eventual treatment
  • Getting products to the market
  • Future developments
  • Other therapeutic targets
  • clock

    17:00

    Chairman's Closing Remarks and Close of Conference

    Workshops

    Marketing Gene Therapies

    Marketing Gene Therapies

    The Hatton, at etc. venues
    26 February 2002
    London, United Kingdom

    Genetic vaccination: new hopes for vaccine development

    Genetic vaccination: new hopes for vaccine development

    The Hatton, at etc. venues
    1 March 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.